Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 19/20 | 0.57 |
| ▸ | PTGDR | Q13258 | 16/20 | 0.57 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.42 |
| ▸ | PTGFR | P43088 | 1/20 | 0.42 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.42 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2924887 | 0.82 | TBXA2R (0.55) | TBXA2RPTGDR | |
| SCHEMBL2925656 | 0.81 | TBXA2R (0.55) | TBXA2RPTGDRPTGER1 | |
| SCHEMBL1254318 | 0.81 | TBXA2R (0.42) | TBXA2RPTGDR | |
| SCHEMBL5774771 | 0.75 | TBXA2R (0.56) | TBXA2RPTGDRPTGER1PTGFRPTGER3 | |
| SCHEMBL2926749 | 0.74 | TBXA2R (0.54) | TBXA2RPTGDRPTGER1PTGFRPTGER3 | |
| SCHEMBL990454 | 0.73 | TBXA2R (1.00) | TBXA2RPTGDRPDE2A | |
| SCHEMBL990995 | 0.72 | TBXA2R (0.73) | TBXA2RPTGDRPTGER1PTGFRPTGER3 | |
| SCHEMBL14449868 | 0.71 | PTGDR (1.00) | TBXA2RPTGDRPDE2A | |
| SCHEMBL1042323 | 0.71 | PTGDR (1.00) | TBXA2RPTGDRPDE2A | |
| SCHEMBL990560 | 0.71 | TBXA2R (0.84) | TBXA2RPTGDRPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2116244-B1 | Method of treating atherosclerosis, dyslipidemias and related conditions | SCHERING CORP (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-1558614-B1 | PYRIDOPYRROLIZINE AND PYRIDOINDOLIZINE DERIVATIVES | MERCK FROSST CANADA LTD (CA) | 2010-09-01 | — | — | EP | disclosed |
| US-20100076002-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions and Pharmaceutical Compositions | CHENG KANG | 2010-03-25 | — | — | US | disclosed |
| EP-2116244-A1 | Method of treating atherosclerosis, dyslipidemias and related conditions | Merck & Co., Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20070299122-A1 | Method of Treating Pathological Blushing | MERCK SHARP & DOHME CORP. | 2007-12-27 | — | — | US | disclosed |
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-27 | — | — | US | disclosed |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-06 | — | — | US | disclosed |
| US-20070244107-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions | MERCK & CO., INC. | 2007-10-18 | — | — | US | disclosed |
| WO-2006052798-A2 | METHOD OF TREATING PATHOLOGICAL BLUSHING | MERCK & CO., INC. (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299122-A1 | Method of Treating Pathological Blushing | BDKRB2, BDKRB1, PTGIR | TBXA2R 9/4885PTGDR 11/4885PTGER1 15/4885 |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | GPR119, FFAR1, HCAR1 | TBXA2R 53/4885PTGDR 518/4885PTGER1 258/4885 |
| US-20100076002-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions and Pharmaceutical Compositions | LDLR, LPAR5, FFAR1 | TBXA2R 44/4885PTGDR 164/4885PTGER1 129/4885 |
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | LDLR, APOB, FFAR1 | TBXA2R 44/4885PTGDR 591/4885PTGER1 268/4885 |
| US-20070244107-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions | LDLR, LIPA, APOB | TBXA2R 68/4885PTGDR 97/4885PTGER1 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.